Aytu BioPharma, Inc. (AYTU)
| Market Cap | 23.25M +37.6% |
| Revenue (ttm) | 57.57M -13.3% |
| Net Income | -14.25M |
| EPS | -1.16 |
| Shares Out | 10.87M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 67,725 |
| Open | 2.180 |
| Previous Close | 2.200 |
| Day's Range | 2.130 - 2.200 |
| 52-Week Range | 1.670 - 3.065 |
| Beta | 0.27 |
| Analysts | Strong Buy |
| Price Target | 9.50 (+343.93%) |
| Earnings Date | Sep 22, 2026 |
About AYTU
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated fo... [Read more]
Financial Performance
In fiscal year 2026, Aytu BioPharma's revenue was $57.57 million, a decrease of -13.27% compared to the previous year's $66.38 million. Losses were -$14.25 million, 5.09% more than in 2025.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AYTU stock is "Strong Buy." The 12-month stock price target is $9.5, which is an increase of 343.93% from the latest price.
News
Aytu BioPharma Transcript: Lytham Partners Fall 2026 Investor Conference
The presentation highlighted the successful launch and strong market positioning of EXXUA, a novel antidepressant with rapid uptake and unique benefits over traditional treatments. Fiscal 2026 saw $57.6 million in revenue, with investments in EXXUA expected to drive future growth and improved financial performance.
Aytu BioPharma Earnings Call Transcript: Q4 2026
Q4 2026 delivered strong EXXUA growth, positive adjusted EBITDA, and stable cash, with disciplined sales force management and favorable gross-to-net economics. ADHD and pediatric portfolios remained durable, supporting investment in EXXUA.
Aytu BioPharma Earnings release: Q4 2026
Aytu BioPharma released its Q4 2026 earnings on September 22, 2026, summarizing the period's financial results.
Aytu BioPharma Annual report: Q4 2026
Aytu BioPharma has published its Q4 2026 annual report on September 22, 2026.
Aytu BioPharma reports Q4 EPS 0c, consensus (35c)
Reports Q4 revenue $16.1M, consensus $12.28M. “Although we remain in the early stages of the EXXUA launch, the continued momentum we saw throughout the fourth quarter further reinforces our confidence...
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 million EXXUA net revenue of $6.6...
Aytu BioPharma Slides: Corporate presentation
Aytu BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on September 22, 2026.
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central...
Aytu BioPharma Transcript: Planet MicroCap Las Vegas 2026
A CNS-focused pharma firm has transformed its business, leveraging a unique pharmacy network to launch EXXUA, a differentiated antidepressant targeting a large unmet need. Early adoption is strong, margins remain robust, and recent financing ensures sufficient runway for growth.
Aytu BioPharma Slides: Corporate presentation
Aytu BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervo...
Aytu BioPharma Transcript: Lytham Partners Spring 2026 Investor Conference
EXXUA, a first-in-class 5-HT1A agonist for MDD, is now the centerpiece of commercial efforts, showing strong early uptake and expected to offset declines in legacy ADHD and pediatric portfolios. Financials reflect a solid cash position, reduced debt, and no need for further capital to reach profitability.
Aytu BioPharma Slides: Corporate presentation
Aytu BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervo...
Aytu BioPharma reports Q3 EPS (53c), consensus (43c)
Reports Q3 revenue $12.41M, consensus $12.05M. “Although we remain in the very early stages of the EXXUA launch, the initial traction we are seeing is highly encouraging,” commented Josh Disbrow,…
Aytu BioPharma Earnings Call Transcript: Q3 2026
EXXUA's first partial launch quarter showed strong early adoption, with over 1,300 prescriptions and $2.4M in revenue, offsetting expected declines in legacy ADHD and pediatric portfolios. Gross margin was 61%, and cash reserves remain solid as the company invests in expanding EXXUA's reach.
Aytu BioPharma Earnings release: Q3 2026
Aytu BioPharma released its Q3 2026 earnings on May 13, 2026, summarizing the period's financial results.
Aytu BioPharma Quarterly report: Q3 2026
Aytu BioPharma has published its Q3 2026 quarterly earnings report on May 13, 2026.
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates Total net revenue of $12.4 millio...
Aytu BioPharma Slides: Corporate presentation
Aytu BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervou...
Aytu BioPharma Slides: Corporate presentation
Aytu BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on April 3, 2026.
Aytu BioPharma Slides: Corporate presentation
Aytu BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on March 17, 2026.
Aytu BioPharma reports Q2 EPS ($1.05) vs. 13c last year
Reports Q2 revenue $15.2M vs. $16.2M last year. Revenue was impacted by a deemphasis in marketing for the ADHD and pediatric portfolios as the company shifted focus to the launch…
Aytu BioPharma Earnings Call Transcript: Q2 2026
Exxua's commercial launch showed strong early adoption, with over 100 prescribers in 27 states and positive patient feedback, while ADHD and pediatric revenues remained stable amid generic competition. Net revenue was $15.2M, with a net loss of $10.6M due to launch investments and non-cash warrant losses.